Cargando…

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

On October 9, 2015, the U.S. Food and Drug Administration expanded the nivolumab metastatic non-small cell lung cancer (NSCLC) indication to include patients with nonsquamous NSCLC after a 3.25-month review timeline. Approval was based on demonstration of an improvement in overall survival (OS) in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kazandjian, Dickran, Suzman, Daniel L., Blumenthal, Gideon, Mushti, Sirisha, He, Kun, Libeg, Meredith, Keegan, Patricia, Pazdur, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2016
Materias:	Regulatory Issues: FDA
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861371/ https://www.ncbi.nlm.nih.gov/pubmed/26984449 http://dx.doi.org/10.1634/theoncologist.2015-0507

Ejemplares similares

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
por: Kasamon, Yvette L., et al.
Publicado: (2017)

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
por: Ning, Yang‐Min, et al.
Publicado: (2017)

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
por: Sul, Joohee, et al.
Publicado: (2016)

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy
por: Larkins, Erin, et al.
Publicado: (2017)

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer
por: Kazandjian, Dickran, et al.
Publicado: (2016)

FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma
por: Richardson, Nicholas C., et al.
Publicado: (2019)

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond
por: Pai‐Scherf, Lee, et al.
Publicado: (2017)

FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis
por: Xu, James Xunhai, et al.
Publicado: (2017)

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations
por: Odogwu, Lauretta, et al.
Publicado: (2018)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
por: Kasamon, Yvette L., et al.
Publicado: (2018)

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
por: Suzman, Daniel L., et al.
Publicado: (2018)

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
por: Fashoyin‐Aje, Lola, et al.
Publicado: (2018)

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy
por: Bhatnagar, Vishal, et al.
Publicado: (2017)

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation
por: Oneal, Patricia A., et al.
Publicado: (2018)

FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
por: Pulte, Elizabeth Dianne, et al.
Publicado: (2018)

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
por: Le, Robert Q., et al.
Publicado: (2018)

FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia
por: Pulte, E. Dianne, et al.
Publicado: (2018)

FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
por: Odogwu, Lauretta, et al.
Publicado: (2017)

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
por: Pelosof, Lorraine, et al.
Publicado: (2018)

FDA expedited approval and implications for rational formulary and health plan design
por: Ferries, Erin A, et al.
Publicado: (2021)

China NMPA perspective on clinical evaluation of SARS-CoV-2 antibody test reagents in the process of emergency approval
por: Lv, Yunfeng, et al.
Publicado: (2020)

Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018
por: Rathi, Vinay K, et al.
Publicado: (2023)

An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression
por: Beaver, Julia A., et al.
Publicado: (2018)

Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science
por: Rouse, Rodney, et al.
Publicado: (2017)

81007 Training Biomedical Engineers in Regulatory Science: Critical Role of Experts from Industry and FDA
por: Lottes, Aaron E., et al.
Publicado: (2021)

Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval
por: Harada, Kenji, et al.
Publicado: (2019)

The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors
por: Tesileanu, C Mircea S, et al.
Publicado: (2023)

Regulatory Issues: PMDA – Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Teserpaturev) for Malignant Glioma
por: Maruyama, Yoshiaki, et al.
Publicado: (2023)

396 Quantitative Analysis of FDA Warning Letters Related to the Use of Social Media Sites in Product Misbranding for the Treatment, Prevention, or Diagnosis of COVID-19
por: Ajaj, Mahmoud, et al.
Publicado: (2023)

Drug Lag and Key Regulatory Barriers in the Emerging Markets
por: Wileman, Harriet, et al.
Publicado: (2010)

Regulations and guidelines governing stem cell based products: Clinical considerations
por: George, Bobby
Publicado: (2011)

Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010)

Registration of Medical Devices
por: George, Bobby
Publicado: (2010)

Implications of ICH-E5: Assessment of drug's sensitivity to ethnic factors and necessity of a bridging study for global drug development
por: Gupta, Sandeep Kumar
Publicado: (2011)

Regulatory requirements for marketing fixed dose combinations
por: Jayasheel, B. G.
Publicado: (2010)

Injury and death in clinical trials and compensation: Rule 122 DAB
por: Ghooi, Ravindra. B.
Publicado: (2013)

Key points of technical review for the registration of SARS-CoV-2 antigen/antibody tests
por: Li, Hongran, et al.
Publicado: (2021)

Key points of technical review for the registration of SARS-CoV-2 nucleic acid tests in China
por: Li, Hongran, et al.
Publicado: (2021)

China's NMPA perspective on the clinical performance of SARS-CoV-2 antigen test reagents
por: Lv, Yunfeng, et al.
Publicado: (2022)

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1b6asc0fqvi6kq7930ah5v2dik